Abstract:
A simple, accurate and precise UV Spectrophotometric methods and RP-HPLC method was developed and validated for simultaneous estimation of Eperisone Hydrochloride and Diclofenac Sodium in bulk and solid dosage form. In Q-absorbance ratio method determination was carried out at 256 nm λmax of Eperisone Hydrochloride and 269 nm an Isobestic point of both the drug. The linearity range was observed between 2-20 μg/ml for both Eperisone hydrochloride and Diclofenac Sodium at their respective wavelengths for both methods. Both the drugs were found in good agreement with the labelled claim in the marketed formulation. In capsule dosage form Eperisone Hydrochloride and Diclofenac Sodium were estimated 101.44 ±0.55 & 101.31±0.97 %. respectively. Second developed UV method was Area under Curve. The method involved the measurement of area at selected analytical wavelength ranges and performing the analysis using “Cramer’s Rule”. Two analytical wavelength ranges selected were A simple, accurate and precise UV Spectrophotometric methods and RP-HPLC method was developed and validated for simultaneous estimation of Eperisone Hydrochloride and Diclofenac Sodium in bulk and solid dosage form. In Q-absorbance ratio method determination was carried out at 256 nm λmax of Eperisone Hydrochloride and 269 nm an Isobestic point of both the drug. The linearity range was observed between 2-20 μg/ml for both Eperisone hydrochloride and Diclofenac Sodium at their respective wavelengths for both methods. Both the drugs were found in good agreement with the labelled claim in the marketed formulation. In capsule dosage form Eperisone Hydrochloride and Diclofenac Sodium were estimated 101.44 ±0.55 & 101.31±0.97 %. respectively. Second developed UV method was Area under Curve. The method involved the measurement of area at selected analytical wavelength ranges and performing the analysis using “Cramer’s Rule”. Two analytical wavelength ranges selected were